Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome

被引：4
|
作者：
Lete, Inaki [1 ,2 ]
Martinez, Ainara [1 ]
Lasaga, Irene [1 ]
Centurion, Eva [1 ]
Vesga, Amaia [1 ]
机构：
[1] Araba Univ Hosp, Obstet & Gynaecol Clin Management Unit, Vitoria, Spain
[2] Araba Univ Hosp, Obstet & Gynaecol Clin Management Unit, Txagorritxu Campus, Vitoria 01009, Spain
来源：
GYNECOLOGICAL ENDOCRINOLOGY | 2024年 / 40卷 / 01期
关键词：
Polycystic ovary syndrome; inositol; MYO/DCI ratio; HUMAN THECAL CELLS; GROWTH-FACTOR-I; FOLLICULAR-FLUID; OOCYTE QUALITY; THERAPEUTIC APPROACH; ANDROGEN PRODUCTION; GENE-PRODUCTS; IGF-II; MYOINOSITOL; WOMEN;
D O I：
10.1080/09513590.2023.2301554
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this article, we present a narrative review on the use of inositol in the treatment of polycystic ovary syndrome (PCOS). Of the different inositols that exist, only myo-inositol (MYO) and D-chiro inositol (DCI) have been studied in the treatment of PCOS. The results of the studies show that there is insufficient or controversial evidence to recommend the use of DCI alone, while MYO alone shows positive results and, above all, the MYO/DCI combination is effective when used at a ratio of at least 40:1, but there is enough rationale to further study ratios such as 66:1 to 100:1 as other possible effective combinations.
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Letter to "May myo-inositol and D-chiro-inositol (40:1) treatment be a good option on normal-weighted polycystic ovary syndrome patients without insulin resistance?"
    Liu, Xin
    Li, Shu-Ping
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2021, 47 (02) : 860 - 860
  • [22] D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review
    Galazis, Nicolas
    Galazi, Myria
    Atiomo, William
    GYNECOLOGICAL ENDOCRINOLOGY, 2011, 27 (04) : 256 - 262
  • [23] Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study
    Kachhawa, Garima
    Kumar, Krithika V. Senthil
    Kulshrestha, Vidushi
    Khadgawat, Rajesh
    Mahey, Reeta
    Bhatla, Neerja
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2022, 158 (02) : 278 - 284
  • [24] Altered D-Chiro-inositol urinary clearance in women with polycystic ovary syndrome
    Baillargeon, JP
    Diamanti-Kandarakis, E
    Ostlund, RE
    Apridonidze, T
    Iuorno, MJ
    Nestler, JE
    DIABETES CARE, 2006, 29 (02) : 300 - 305
  • [25] Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients
    Monastra, Giovanni
    Unfer, Vittorio
    Harrath, Abdel Halim
    Bizzarri, Mariano
    GYNECOLOGICAL ENDOCRINOLOGY, 2017, 33 (01) : 1 - 9
  • [26] Effects of D-chiro-inositol and myo-inositol on the cataractogenesis of the xylose-induced rat lenses
    Lee, WK
    Kim, H
    FASEB JOURNAL, 2002, 16 (04): : A640 - A640
  • [27] The D-chiro-inositol paradox in the ovary
    Carlomagno, Gianfranco
    Unfer, Vittorio
    Roseff, Scott
    FERTILITY AND STERILITY, 2011, 95 (08) : 2515 - 2516
  • [28] The Combined therapy with myo-inositol and D-Chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone
    Nordio, M.
    Proietti, E.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2012, 16 (05) : 575 - 581
  • [29] Myo-inositol vs. D-chiro inositol in PCOS treatment
    Formuso, C.
    Stracquadanio, M.
    Ciotta, L.
    MINERVA GINECOLOGICA, 2015, 67 (04): : 321 - 325
  • [30] The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial
    Colazingari, Sandra
    Treglia, Mariangela
    Najjar, Robert
    Bevilacqua, Arturo
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2013, 288 (06) : 1405 - 1411
12345